Table 1.
Baseline characteristics of the PS-matched GLP-1 RA cohorts
| Baseline characteristics | Once-weekly GLP-1 RAs n = 784 |
Daily GLP-1 RAs n = 784 |
SMD |
|---|---|---|---|
| Age, years, mean (SD) | 54.6 (9.9) | 54.4 (10.2) | 0.02 |
| Women, n (%) | 392 (50.0) | 402 (51.3) | 0.03 |
| Weight, kg, mean (SD) | 107.0 (23.7) | 107.9 (24.6) | – 0.04 |
| Body mass index, kg/m2, mean (SD) | 36.5 (7.4) | 36.7 (7.3) | – |
| HbA1c, %, mean (SD) | 8.5 (1.6) | 8.4 (1.7) | 0.05 |
| CCI score, mean (SD) | 0.5 (0.9) | 0.5 (1.0) | 0.01 |
| Baseline antidiabetic medication, number of claims (%) | |||
| Metformin | 634 (45.5) | 618 (47.8) | – 0.01 |
| DPP-4is | 253 (18.1) | 237 (18.3) | – 0.02 |
| SGLT-2is | 161 (11.5) | 69 (5.3) | – |
| Sulfonylureas | 313 (22.5) | 302 (23.4) | 0.00 |
CCI Charlson Comorbidity Index, DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1 RA glucagon-like peptide-1 receptor agonist, HbA1c glycated haemoglobin, PS propensity score, SD standard deviation, SGLT-2i sodium–glucose cotransporter-2 inhibitor; SMD standardized mean difference